Navigation Links
Drug Development in Arizona Gets Boost Following ASU-Quintiles Agreement
Date:9/17/2010

PHOENIX, Sept. 17 /PRNewswire/ -- Arizona's contribution to the accelerated development of new, safe and effective medicines to help treat suffering patients in the US and around the world, will become greater following the signing of new deal between Arizona State University and Quintiles (www.quintiles.com), a global integrated biopharmaceutical services company which is a leader in managing clinical research.

The Center for Healthcare Innovation & Clinical Trials (https://nursingandhealth.asu.edu/clinical-trials).at ASU – part of the College of Nursing & Health Innovation – is only the fifth organization in the world to become a global prime site partner for Quintiles.

Through Quintiles the Center will receive access to many more clinical research initiatives. In return, the Center will deploy its unique community-based model to recruit more physicians and nurse practitioners who can identify patients who are willing and eligible to participate in the research.

Access to patients to participate in clinical trials is one of the major barriers to bringing much needed safe and effective drugs to market faster and with less cost.

Linda Mottle, Director of the Center for Healthcare Innovation & Clinical Trials at ASU, noted that the clinical research market in Arizona lags other states with comparable population sizes and explained: "We believe our community-based model can substantially increase the clinical research market in Arizona."

Adam Chasse, Senior Director for Patient Access at Quintiles, added: "Access to patients is one of the toughest hurdles in working with our biopharmaceutical customers to accelerate outcomes and get better value from the drug development process.  This agreement with ASU will help our customers to meet study milestones more effectively by providing access to large groups of physicians, known as 'investigators,' who are interested in participating in clinical research and who treat large groups of patients."

The ASU center is the only one of Quintiles' five global prime sites that is a community-based, non-academic medical center. ASU's model, the Community Oriented Network to Enhance Clinical Trials and Research (CONECTR), will serve as the hub for placing, subcontracting, consulting and supporting multi-phased research studies within Arizona.

Ken Levin, Chief Executive Officer of Precision Trials and a member of the Center Advisory Board, sees CONECTR providing multiple benefits for community research organizations:  "By offering assistance and support to providers, CONECTR will increase the number of qualified investigators and sites conducting research in Arizona. The program aligns clinical research pipeline opportunities with local investigators by their capability."

Quintiles' other prime site partners are Kaiser Permanente in Southern California, the University of Pretoria in South Africa, Queen Mary's College in London, Washington Hospital Center in Washington, D.C., and the University of Malaya in Malaysia.


'/>"/>
SOURCE Arizona State University College of Nursing & Health Innovation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DNASequencing.com and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Epik.com Domain Development Conference
2. Oxford Finance Corporation Hires Dr. Killu Sanborn to Support Life Science Business Development in Western North America
3. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
4. Zero Discharge Sweet Sorghum Ethanol Process Development
5. NASA funds development of nanoscale materials for high energy density lithium-ion batteries
6. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
7. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
8. Torbjorn Bjerke Appointed as new CEO for Karolinska Development
9. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
10. Clean Power Development, LLC Urges Sustainable, Community-Centric Approach to Biomass Energy
11. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 2017 , ... NetDimensions has been ranked as a Leader ... Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who possess comprehensive ... those strategies. NetDimensionsā€™ ranking as a Leader due to its strengths in: , ...
(Date:5/23/2017)... Diego, CA (PRWEB) , ... May 23, 2017 , ... ... matrix of polymeric molecules, can cause diverse pathologies ranging from food poisoning and catheter ... impact of biofilms is in the tens of billions of dollars per year, there ...
(Date:5/22/2017)... ... 22, 2017 , ... Cancer diagnostics and pathology workflow solution ... the Association for Pathology Informatics Annual Summit at the Wyndham Grand ... Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research it led to ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs ... the Prince Of Wales Private Hospital. The procedure was performed on a 46-year-old ... failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is ...
Breaking Biology Technology:
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):